Tags

Type your tag names separated by a space and hit enter

Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study.
J Clin Hypertens (Greenwich). 2010 Dec; 12(12):917-26.JC

Abstract

Patients with stage 2 hypertension (systolic blood pressure [SBP] ≥160mm Hg and/or diastolic blood pressure [DBP] ≥100mm Hg) are at high cardiovascular risk and require intensive blood pressure (BP)-lowering therapy. This randomized double-blind study is the first prospective trial specifically designed to evaluate the direct renin inhibitor aliskiren in patients with a mean sitting SBP ≥160 mm Hg and <180mm Hg (the lower ranges of stage 2 systolic hypertension). After a 2- to 4-week washout period, 688 patients were randomized to once-daily aliskiren/hydrochlorothiazide (HCT) 150/12.5mg or aliskiren 150mg for 1 week and then double the doses for 11 weeks. Baseline BP was 167.1/95.0mm Hg. At week 12, both aliskiren/HCT and aliskiren provided substantial BP reductions from baseline (30.0/12.6 mm Hg and 20.3/8.2 mm Hg, respectively). Aliskiren/HCT lowered BP significantly more than aliskiren (least-squares mean between-treatment differences [95% confidence interval] were -9.7 [-12.0 to -7.4] for SBP and -4.5 [-5.8 to -3.2] for DBP; both P<.0001). Similar BP reductions were seen in the subgroups of patients with isolated systolic hypertension and obesity. Aliskiren, with or without HCT, provides clinically significant BP reductions and may therefore be an effective treatment option in patients with stage 2 hypertension.

Authors+Show Affiliations

New York University School of Medicine, New York, NY, USA. hrbmd63@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21122057

Citation

Black, Henry R., et al. "Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: the ACQUIRE Randomized Double-blind Study." Journal of Clinical Hypertension (Greenwich, Conn.), vol. 12, no. 12, 2010, pp. 917-26.
Black HR, Kribben A, Aguirre Palacios F, et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich). 2010;12(12):917-26.
Black, H. R., Kribben, A., Aguirre Palacios, F., Bijarnia, M., Laflamme, A. K., & Baschiera, F. (2010). Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. Journal of Clinical Hypertension (Greenwich, Conn.), 12(12), 917-26. https://doi.org/10.1111/j.1751-7176.2010.00378.x
Black HR, et al. Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: the ACQUIRE Randomized Double-blind Study. J Clin Hypertens (Greenwich). 2010;12(12):917-26. PubMed PMID: 21122057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. AU - Black,Henry R, AU - Kribben,Andreas, AU - Aguirre Palacios,Fernando, AU - Bijarnia,Mahendra, AU - Laflamme,Annik K, AU - Baschiera,Fabio, Y1 - 2010/10/04/ PY - 2010/12/3/entrez PY - 2010/12/3/pubmed PY - 2011/3/18/medline SP - 917 EP - 26 JF - Journal of clinical hypertension (Greenwich, Conn.) JO - J Clin Hypertens (Greenwich) VL - 12 IS - 12 N2 - Patients with stage 2 hypertension (systolic blood pressure [SBP] ≥160mm Hg and/or diastolic blood pressure [DBP] ≥100mm Hg) are at high cardiovascular risk and require intensive blood pressure (BP)-lowering therapy. This randomized double-blind study is the first prospective trial specifically designed to evaluate the direct renin inhibitor aliskiren in patients with a mean sitting SBP ≥160 mm Hg and <180mm Hg (the lower ranges of stage 2 systolic hypertension). After a 2- to 4-week washout period, 688 patients were randomized to once-daily aliskiren/hydrochlorothiazide (HCT) 150/12.5mg or aliskiren 150mg for 1 week and then double the doses for 11 weeks. Baseline BP was 167.1/95.0mm Hg. At week 12, both aliskiren/HCT and aliskiren provided substantial BP reductions from baseline (30.0/12.6 mm Hg and 20.3/8.2 mm Hg, respectively). Aliskiren/HCT lowered BP significantly more than aliskiren (least-squares mean between-treatment differences [95% confidence interval] were -9.7 [-12.0 to -7.4] for SBP and -4.5 [-5.8 to -3.2] for DBP; both P<.0001). Similar BP reductions were seen in the subgroups of patients with isolated systolic hypertension and obesity. Aliskiren, with or without HCT, provides clinically significant BP reductions and may therefore be an effective treatment option in patients with stage 2 hypertension. SN - 1751-7176 UR - https://www.unboundmedicine.com/medline/citation/21122057/Aliskiren_alone_or_in_combination_with_hydrochlorothiazide_in_patients_with_the_lower_ranges_of_stage_2_hypertension:_The_ACQUIRE_randomized_double_blind_study_ L2 - https://doi.org/10.1111/j.1751-7176.2010.00378.x DB - PRIME DP - Unbound Medicine ER -